Amgen Option Alert: Apr 17 $320 Calls at the Bid: 4548 vs 290 OI

Amgen Option Alert: Apr 17 $320 Calls at the Bid: 4548 @ $1.92 vs 290 OI; Ref=$295.9704

Amgen (NASDAQ:AMGN) 주식

Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Eli Lilly

Biotech

Health Care

Trading Ideas

AMGN

일라이 릴리(NYSE:LLY) 주가는 목요일(17일)에 25년 만에 최대 일일 랠리를 기록했다. 이는 체중감량 약물 시장에서의 리더십을 확립할 수 있는 주요 임상 시험 데이터를 공개했기 때문이다. 체중감량 시장은 2030년까지 3배 이상 성장할 것으로 예상된다.

일라이 릴리, 경구용 체중감량 신약 임상 성공으로 주가 14% 폭등···애널리스트 반응은?

Eli Lilly and Co.

Equities

Government

News

Markets

ABBV

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

REGN

도널드 트럼프 대통령은 수요일(9일) 상호관세를 90일 동안 일시 중단했지만, 나중에 집무실에서 기자들과의 대화에서 제약 회사들이 관세에 직면할 것이라고 확인했다. 

트럼프의 의약품 관세 확인...일라이릴리·애브비·리제네론·브리스톨 등 제약주 급락

Cathie Wood Offloads Meta Stock While Mark Zuckerberg Celebrates Llama AI Success

ETFs

ABSI

ARKG

ARKK

ARKQ

ARKX

BEAM

ILMN

IRDM

PACB

RPTX

VEEV

2025년 3월 21일 금요일, 캐시 우드가 이끄는 아크 인베스트는 몇 가지 주목할 만한 거래를 진행했으며, 여기에는 상당한 매수와 매도가 포함되었다. 아크 인베스트의 펀드는 이리듐 커뮤니케이션스(NASDAQ:IRDM), 빔 테라퓨틱스(NASDAQ:BEAM), 퍼시픽 바이오사이언스 오브 캘리포니아(NASDAQ:PACB), 및 앱시 코퍼레이션(NASDAQ:ABSI)를 매수한 반면, 일루미나(NASDAQ:ILMN), 리페어 테라퓨틱스(NASDAQ:RPTX), 암젠(NASDAQ:AMGN), 및 비바 시스템즈(NYSE:VEEV)의 주식을 매도했다.

아크 인베스트가 이리듐·빔·퍼시픽 바이오사이언스를 매수, 일루미나와 암젠을 매각

Amgen Inc

General

Amgen Pledges $900M, 350 New Jobs In Ohio

Amgen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NYSE">AMGN</a>) short percent of float has fallen 6.76% since its last report. The company recently reported that it has 14.08 million shares sold short, which is 2.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Amgen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745416832_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Amgen has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Amgen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Amgen's peer group average for short interest as a percentage of float is 5.89%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on Amgen?

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/21/final-trades-take-two-interactive-franco-nevada-amgen-and-the-10-year-treasury.html">Halftime Report Final Trades</a>,&#8221; Brian Belski of BMO Capital Markets named Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) as <a href="https://www.benzinga.com/quote/TTWO/earnings">his final trade</a>.
On the earnings front, Take-Two Interactive Software will report financial results for its fourth quarter, after the closing bell on Thursday, May 15. Analysts expect the company to report a quarterly loss at 6 cents per share on revenue of $1.55 billion.
Amy Raskin, CIO at Chevy Chase Trust picked Franco-Nevada Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) as her final trade.
Supporting her choice, Scotiabank analyst Tanya Jakusconek raised the price target on the stock from $150 to $165 on April 14.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Stephen L. Weiss of Short Hills Capital Partners selected the U.S. 10-year Treasury.
Joseph M. Terranova of Virtus Investment Partners named Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) as his final trade.
Supporting his view, UBS analyst Colin Bristow maintained Amgen with a Neutral rating on April 14 and raised the price target from $315 to $319.
Price Action:
<ul>
<li>Take-Two Interactive shares fell 3.6% to close at $205.16 on Monday.</li>
<li>Franco-Nevada gained 1.2% to close at $173.18 during Monday's session.</li>
<li>Amgen shares fell 1.3% to close at $273.68 on Monday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44895495/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

TTWO

Amgen, Franco-Nevada, Take-Two Interactive And More: CNBC's 'Final Trades'

Analyst Ratings

CNBC Halftime Report Final Trades: Take-Two Interactive Software, Franco-Nevada, Amgen

Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple <a href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential">in size by 2030. </a>
The stock surged, closing the day up 14.36% to $839.96, marking its best performance since June 2000.
In a Thursday note, Goldman Sachs analyst Asad Haider, CFA said Eli Lilly's first Phase 3 trial of orforglipron — a once-daily oral treatment for type 2 diabetes and obesity — hit its top-line targets with best-case scenario results across weight loss, blood sugar control and safety.
<h1 class="wp-block-heading">The Data That Moved the Market</h1>
Lilly's ACHIEVE-1 trial evaluated orforglipron, an oral GLP-1 (glucagon-like peptide-1) receptor agonist, in adults with type 2 diabetes. 
At the highest 36mg dose, patients saw an average weight reduction of 7.9% over 40 weeks — translating to 16 pounds of weight loss, substantially above the placebo-adjusted rate of 6.3%.
For context, that outperforms Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) 's Rybelsus — currently the only oral GLP-1 treatment available — which achieved a 4.9% weight loss at its peak dosage in the SUSTAIN-1 trial.
In addition, orforglipron delivered A1C reductions of up to 1.6%, aligning with injectable semaglutide's performance and hitting a critical target in glycemic control. 
More than 65% of participants on the highest dose achieved an A1C level at or below 6.5%, a threshold defined by the American Diabetes Association as the benchmark for controlled diabetes.
Discontinuation due to side effects was 8% at the top dose, and there were no reported liver injury signals — two key safety indicators watched closely by investors after setbacks in rival studies.
<h1 class="wp-block-heading">Why Wall Street Is Cheering</h1>
Goldman Sachs analysts wrote that the trial marks "an important clearing event for LLY shares," especially after recent disappointments from rivals like Novo Nordisk A/S and Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) in their respective obesity pipelines. 
The investment bank reiterated a Buy rating and $888 price target on the stock, citing Lilly's potential to dominate a market expected to balloon from $28 billion today to $95 billion by 2030.
Their internal forecasts see risk-adjusted peak sales for orforglipron hitting $23.5 billion by 2035, with commercial rollout starting globally in 2026. That's well above the Street's consensus of $16.8 billion.
"This data trends toward our bull case scenario," Goldman said, noting that investor caution ahead of the binary trial event was likely keeping shares from rallying sooner.
<h1 class="wp-block-heading">Is Orforglipron The ‘Ozempic In A Pill'?</h1>
Tim Anderson, equity analyst at Bank of America, said Thursday's results were "pretty much a best-case scenario," covering all four key investor watchpoints: weight loss, blood sugar control, tolerability and safety.
Calling orforglipron a potential "Ozempic in a pill," Anderson highlighted its small molecule structure as a key differentiator. 
Unlike Novo's Rybelsus, which is a peptide with cold-chain storage limitations, orforglipron's easier manufacturing and oral delivery method could unlock demand in emerging markets, where injectables face logistical hurdles.
"Positive results like these, in a skittish market, should be received well," Anderson said, adding that the company remains one of the two dominant incumbents in the diabetes and obesity drug space.
Bank of America reiterated its Buy rating and $1,000 price objective, citing Eli Lilly's superior growth metrics: while the stock trades at roughly three times the average pharma price-to-earnings multiple, its expected earnings-per-share growth is five to six times higher than peers, making it relatively attractive on a PEG basis.
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44873779/wall-street-rebounds-eli-lilly-rallies-unitedhealth-group-plummets-whats-driving-markets-thursday">Wall Street Rebounds, Eli Lilly Rallies, UnitedHealth Group Plummets: What&#8217;s Driving Markets Thursday?</a></li>
</ul>

Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React

UBS analyst Colin Bristow maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Neutral and raises the price target from $315 to $319.

Price Target

UBS Maintains Neutral on Amgen, Raises Price Target to $319

Sandoz Group AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZNY#OTC">SDZNY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZXF#OTC">SDZXF</a>) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept), first approved by the U.S. Food and Drug <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Administration (FDA) in 1998</a>.
Etanercept is a biologic medicine used to treat various inflammatory diseases.
Sandoz <a target="_blank" href="https://www.sandoz.com/sandoz-files-antitrust-litigation-against-amgen-regarding-patient-access-etanercept-biosimilar-us/" rel="noreferrer noopener">alleges</a> that Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz etanercept biosimilar, Erelzi+&nbsp;(etanercept-szzs), by unlawfully purchasing and using certain patent rights to entrench its position in the market.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44647281/fda-approves-amgens-uplizna-as-first-drug-for-chronic-immune-mediated-fibroinflammatory-disorder" rel="noreferrer noopener">FDA Approves Amgen&#8217;s Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder</a>
In 2024, Enbrel generated $3.3 billion in revenue in the U.S.
Sandoz received FDA approval for Erelzi in 2016, the same year the company launched the medicine in Europe.
Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and allow Sandoz to launch Erelzi as soon as possible.
The company is also seeking damages, which could be tripled under applicable laws. The lawsuit was filed in the U.S. District Court for the Eastern District of Virginia.
Erelzi is the Sandoz biosimilar of the reference medicine Enbrel. Erelzi has been studied in a global development program, which included a comprehensive comparison of Erelzi and Enbrel&nbsp;at the analytical, preclinical, and clinical levels.
The program included preclinical studies, pharmacokinetic (PK) studies, and the Phase 3 confirmatory safety and efficacy EGALITY study.
The FDA approved Erelzi for the following indications: adult rheumatoid arthritis (RA), ankylosing spondylitis (AS), polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA) and moderate to severe plaque psoriasis (PsO).
In April 2024,&nbsp;Sandoz <a target="_blank" href="https://www.sandoz.com/sandoz-reaches-agreement-amgen-resolving-all-patent-litigation-related-its-us-denosumab-biosimilars/" rel="noreferrer noopener">agreed</a> to resolve all patent disputes relating to the FDA-approved Sandoz denosumab biosimilars with Amgen.
Patent infringement proceedings were initially filed by Amgen in the U.S. Federal District Court for the District of New Jersey in May of 2023.&nbsp;&nbsp;
Amgen claimed that Sandoz infringed up to 21 patents expiring as late as 2037, protecting reference medicines Prolia and Xgeva.
Under the agreement, Sandoz could enter the U.S. market with a biosimilar version of Prolia and Xgeva on May 31, 2025, or earlier, under certain circumstances if customary acceleration provisions are triggered.
Sandoz received FDA approval for the first and only denosumab biosimilars, Jubbonti&nbsp;and Wyost, on March 5, 2024.
Jubbonti&nbsp;and Wyost are interchangeable with and approved by the FDA for all indications of reference medicines Prolia&nbsp;and Xgeva.
They have the same dosage form, route of administration, dosing regimen, and presentation as the respective reference medicines.
On Friday, Amgen&nbsp;said that the global Phase 3 DeLLphi-304 trial of Imdelltra&nbsp;(tarlatamab-dlle) met its primary endpoint at a planned interim analysis for small cell lung cancer patients who progressed on or after a single line of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44760384/imdelltra-demonstrated-superior-overall-survival-in-small-cell-lung-cancer" rel="noreferrer noopener">platinum-based chemotherapy</a>.
Imdelltra demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to local standard-of-care chemotherapy.
The safety profile for Imdelltra was consistent with its known profile. Detailed data from DeLLphi-304 will be presented at an upcoming medical congress.
Price Action: AMGN stock is up 0.97% at $288.74 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" target="_blank" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a></li>
</ul>

Large Cap

Legal

SDZNY

SDZXF

Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug

<ul>
<li>Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel&#xAE;&#x2A; for US patients with disabling inflammatory diseases</li>
<li>Despite FDA approval nearly a decade ago, etanercept biosimilar continues to be blocked</li>
<li>Sandoz seeking damages in addition to clearing path for launch</li>
</ul>

Sandoz Targets Amgen With Antitrust Suit To Unblock Market Entry Of Enbrel Biosimilar For U.S. Patients

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy

Amgen Announced Global Phase 3 DeLLphi-304 Clinical Trial Evaluating IMDELLTRA As Treatment For Patients With Small Cell Lung Cance Met Its Primary Endpoint

Even as President Donald Trump paused the reciprocal tariffs for 90 days on Wednesday, he later confirmed in a conversation with reporters at his Oval Office that pharmaceutical companies would face tariffs.
What Happened: The rally in pharma stocks was short-lived after the stocks reversed course on Thursday. When a reporter asked President Trump if he would go ahead and levy tariff duties on pharmaceutical stocks, he said, &#8220;Yeah, well, I will be because we want them coming back.&#8221;
&#8220;You know, we realized during COVID-19 that we don&#8217;t make our drugs and our pharmaceuticals in this country. So, I realized that, and it was a big realization,&#8221; he added.
Citing the emergency during COVID-19, he stated that he wanted the pharma companies to produce drugs in the U.S.
&#8220;We had to go to China to get drugs, we had to go to other places, we don&#8217;t make it. That&#8217;s because we let them leave, and now if they want to come back, we&#8217;re going to put tariffs on the pharmaceutical companies, and they&#8217;re going to all want to come back,&#8221; Trump said.
The pharma stocks tumbled on Thursday after Trump&#8217;s confirmation of tariffs.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>Thursday&#8217;s Performance</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>-4.35%</td>
<td>-7.35%</td>
<td>-5.09%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>-3.14%</td>
<td>-2.92%</td>
<td>3.99%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-6.10%</td>
<td>-11.15%</td>
<td>2.73%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-5.26%</td>
<td>-23.60%</td>
<td>-40.63%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.87%</td>
<td>-18.87%</td>
<td>-18.03%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>-3.66%</td>
<td>10.36%</td>
<td>47.71%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-5.32%</td>
<td>-21.80%</td>
<td>-38.53%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>-3.33%</td>
<td>8.54%</td>
<td>4.23%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>-1.51%</td>
<td>3.24%</td>
<td>-0.07%</td>
</tr>
</tbody>
</table>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/04/44755181/pentagon-slashes-5-1-billion-in-accenture-deloitte-booz-allen-contracts-thats-a-lot-of-consulting">Pentagon Slashes $5.1 Billion In Accenture, Deloitte, Booz Allen Contracts: &#8216;That&#8217;s A Lot Of Consulting&#8217;</a>
Why It Matters: Despite a 90-day pause on reciprocal tariffs, base global tariffs of 10% and China tariffs of 125%, along with sector-specific tariffs of 25% on steel and aluminum, auto, and auto parts remain in place. Adding to it, the President hinted that he could soon announce tariffs on pharmaceutical companies.
Here are some of the pharmaceutical industry-linked exchange-traded funds that could be impacted.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>-7.02%</td>
<td>-7.51%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-7.04%</td>
<td>-6.08%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-10.13%</td>
<td>-4.37%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-14.05%</td>
<td>-11.45%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>2.88%</td>
<td>0.35%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-11.54%</td>
<td>-10.18%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-41.35%</td>
<td>-43.86%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: After Thursday&#8217;s fall, following Wednesday&#8217;s rebound, the Nasdaq 100 index was 17.46% lower than its previous high of 22,222.61 points. The S&amp;P 500 index was down 14.31% from its record of 6,147.43 points, and the Dow Jones declined 12.16% from its 52-week high of 45,073.63 points.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, ended lower on Thursday. The SPY was down 4.38% to $524.58, while the QQQ declined 4.25% to $446.18, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44728276/spy-qqq-call-volumes-spiked-minutes-before-tariff-pause-announcement-alexandria-ocasio-cortez-demands-disclosure-from-congress-members" target="_blank" rel="noreferrer noopener">SPY, QQQ Call Volumes Spiked Minutes Before Tariff Pause Announcement: Alexandria Ocasio-Cortez Demands Disclosure From Congress Members</a></li>
</ul>
Photo courtesy: Shutterstock

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies

Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Equal-Weight and raises the price target from $328 to $330.

Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $330

President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on <a href="https://in.benzinga.com/markets/25/04/44627820/trumps-reciprocal-tariffs-on-india-exempt-pharma-easing-mark-cubans-price-hike-concerns">pharmaceuticals imported from foreign countries.</a>
What Happened: President Trump, on Tuesday, disclosed plans for a &#8220;major tariff&#8221; on foreign pharmaceuticals. Trump is hopeful that this move will prompt drug companies to shift their operations to the U.S., <a href="https://www.theguardian.com/australia-news/2025/apr/09/donald-trump-flags-major-tariff-on-pharmaceuticals-as-us-senator-criticises-whack-on-australia">reported</a> The Guardian.
&#8220;We&#8217;re going to be announcing very shortly a major tariff on pharmaceuticals&#8230; when they hear that they will leave China, they will leave other places because&#8230; most of their product is sold here,&#8221; Trump expressed at a National Republican Congressional Committee dinner.
Despite exempting pharmaceuticals from the recent round of reciprocal tariffs, Trump has been hinting for a long time that the drug industry would be a target. The President is of the view that the tariff will drive drug companies to return to the U.S., considering it is a significant market for their products. &#8220;The advantage we have over everybody is that we&#8217;re the big market. So we&#8217;re going to be announcing very shortly a major tariff on pharmaceuticals,&#8221; Trump added.
The President, however, did not divulge any specifics regarding the tariff increase or its potential impact.
Pharmaceutical stocks across the globe, including GlaxoSmithKline, Sanofi and India&#8217;s Teva Pharmaceuticals, tumbled on Wednesday.
In the U.S. pharmaceutical stocks, Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) declined 3.5%, while Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) lost 3.2%. AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) fell 1.35%, while Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) dropped 2.94% and 2.75%, respectively, during the Wednesday pre-market trading session.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/25/04/44706492/trump-predicts-tremendous-thundering-landslide-in-2026-midterms-says-tariffs-will-help-republicans-win-bi" target="_blank" rel="noreferrer noopener">Trump Predicts &#8216;Tremendous, Thundering Landslide&#8217; In 2026 Midterms, Says Tariffs Will Help Republicans Win Big</a>
Why It Matters: The $1.7 trillion revenue prescription drug industry has demonstrated a strong resilience to tariffs. The U.S., being the largest and most profitable market globally for prescription drugs and generic products, imports most of these from overseas. In 2024, drug imports reached $213 billion, more than two and a half times the total 10 years earlier. The proposed tariff could, in theory, help bring business back onshore.
However, companies like&nbsp;AstraZeneca Plc and&nbsp;Pfizer&nbsp;have extensive global manufacturing networks, including Ireland, Germany, Canada, the UK, and the U.S and are not restricted to India and China. Sources told Reuters that it could take up to 10 years to build and equip a factory in the U.S., due to stringent regulatory requirements from the U.S. Food and Drug Administration (FDA). Therefore, Trump&#8217;s tariff might necessitate drugmakers to overhaul a complex, expensive manufacturing system.
Meanwhile, after Trump indicated major tariffs on pharmaceuticals, EU drugmakers have urged European Commission President Ursula von der Leyen to take "rapid and radical action" to address the growing "risk of an exodus" to the U.S., following a meeting in Brussels.
<ul>
<li>READ MORE: <a href="https://benzinga.com/25/04/44705972/ford-motor-general-motors-to-witness-higher-demand-as-american-automotives-reap-the-fruit-of-protectionism-says-e" target="_blank" rel="noreferrer noopener">Ford, GM To Witness &#8216;Higher Demand&#8217; As American Carmakers Set To &#8216;Reap The Fruit Of Protectionism,&#8217; Says Expert: Here&#8217;s A List Of Potential Gainers And Losers From Trump Tariffs</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market

Looking into the current session, Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares are trading at $289.09, after a 1.80% decrease. Over the past month, the stock fell by 9.34%, but over the past year, it actually spiked by 6.93%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1744041619_0.png" alt="Past Year Chart" />

<h3>Evaluating Amgen P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Amgen has a lower P/E than the aggregate P/E of 79.13 of the Biotechnology industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744041619_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Amgen

Global

European Medicines Agency Says Amgen To Stop Marketing All Strengths Of Mimpara Tablets In EU/EEA Markets Due To Commercial Reasons

Several exemptions exist among President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted" target="_blank" rel="noopener">broad tariffs</a>, which were announced on Wednesday. 
The biopharma industry has historically been shielded from tariffs, including during Trump&#8217;s first term. Given its significant manufacturing presence in Europe, investors had feared global tariffs could disrupt the sector.
Morningstar <a href="https://www.morningstar.com/stocks/biopharma-industry-exempt-global-10-tariff-we-still-see-margin-tax-rate-risks" target="_blank" rel="noopener">reports</a> that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have cost the industry $20 billion, with some of the largest firms facing annual tariffs of up to $1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44642463/french-president-macron-suggests-suspension-of-eu-investments-in-us-amid-tariff-turmoil" rel="noreferrer noopener">French President Macron Suggests Suspension Of EU Investments In US Amid Tariff Turmoil, Vows &#8216;More Powerful&#8217; Response</a>
Goldman Sachs expects continued volatility in the biotechnology sector (XBI and S&amp;P 500 are down about 14% and 7% year-to-date, respectively), driven by broader economic <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more" rel="noreferrer noopener">uncertainty and unclear healthcare policy</a>.
Analyst Salveen Richter has analyzed geographic exposure and tax rates for individual companies and sees Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) and Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) in the strongest position, followed by Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often import ingredients or finished products into the U.S.
Analyst Richter adds that <a target="_blank" href="https://www.benzinga.com/quote/AMGN" rel="noreferrer noopener">Amgen</a>, <a target="_blank" href="https://www.benzinga.com/quote/ALNY" rel="noreferrer noopener">Alnylam</a>, <a target="_blank" href="https://www.benzinga.com/quote/BIIB" rel="noreferrer noopener">Biogen</a>, and <a target="_blank" href="https://www.benzinga.com/quote/REGN" rel="noreferrer noopener">Regeneron</a> are the least exposed to Medicaid risk.
Goldman Sachs said Friday that it&#8217;s been hard to measure the exact impact of potential tariffs on U.S. biopharma due to limited public data on where drugs are made.
Their analysis shows limited manufacturing exposure to Canada, Mexico and China. Pharmaceuticals from Canada and Mexico are also likely exempt under the USMCA trade deal. However, some companies do rely heavily on manufacturing in the EU.
If tariffs are placed on drugs made outside the U.S. and kept in place, they could raise manufacturing costs. Companies often import ingredients or finished products before selling them in the U.S. Some manufacturers are reportedly speeding up shipments from Europe out of concern that tariffs may apply to <a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noopener">those products,</a><a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noreferrer noopener"> too</a>.
Goldman Sachs is also watching for exceptions or phased rollouts, pointing to a similar eight-year grace period in the Biosecure Act.
Still, the analyst writes that biopharma companies are generally resilient due to their high profit margins and globally spread operations.
Companies that produce small-molecule drugs might handle a U.S. manufacturing shift better than those making biologics since small molecules require less complex production.
Senator Ron Wyden has raised concerns about Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) using offshore setups to reduce U.S. taxes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44648087/karman-strikes-90m-deal-for-mti-enhancing-position-in-next-gen-defense-technologies" target="_blank" rel="noreferrer noopener">Karman Strikes $90M Deal For MTI, Enhancing Position In Next-Gen Defense Technologies</a></li>
</ul>
Photo: Shutterstock

ALNY

BIIB

VRTX

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks

Dip-buying remained absent in early Friday trading in New York, with Wall Street deep in the red as global trade war fears continued to escalate, despite the March jobs report showed continued signs of <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645518/strong-jobs-report-offers-hope-but-will-it-be-enough-to-counter-tariff-turmoil">U.S. labor market resilience. </a>
The U.S. economy added 228,000 jobs in March—the strongest gain since December 2024—sharply beating expectations of 135,000, according to figures released by the Bureau of Labor Statistics.
Still, the report did little to calm nerves. Investors fear it may be the last strong print for a while, with the economic impact of rising tariffs expected to seep into the data in the coming months.
The unemployment rate ticked up just 0.1 percentage points to 4.2%, remaining low by historical standards, while wage growth broadly aligned with forecasts. Average hourly earnings rose 0.3% month-over-month and 3.8% year-over-year.
Wall Street remained deep in the red after China announced a retaliatory 34% tariff on U.S. goods—matching the rate imposed by President Donald Trump on Wednesday—intensifying fears of a full-blown trade war.
Trump took to Truth Social on Friday. "Great job numbers, far better than expected. It's already working. Hang tough, we can't lose!"
He added. "China played it wrong, they panicked," and reassured investors: "This is a great time to get rich—richer than ever before!"
Investors are now on edge, awaiting remarks from Fed Chair Jerome Powell at 11:25 a.m. ET on Friday, hoping for any hint of a dovish shift in policy tone.
<h3 class="wp-block-heading">Wall Street In Bloodbath: Could Powell Halt The Bleeding? </h3>
Here's how the key benchmarks moved at the open:
<ul>
<li>S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), was down 2.9% by 9:55 a.m. in New York.</li>
<li>Dow Jones Industrial Average, tracked by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), fell 2.6%, officially entering correction territory after falling more than 10% from its late-2024 peak.</li>
<li>Nasdaq-100, tracked by the Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), fell 2.9%, hitting a 20% decline from all-time highs, entering a bear market. </li>
<li>Russell 2000, represented by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), fell 4.1%. </li>
</ul>
Every sector traded in the red, with heaviest losses concentrated in Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), down 5%, and Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>), down 4%. 
While stocks continued to slump, bonds attracted haven flows. Yields on 10-year Treasury notes fell by 10 basis points to 3.94%. The popular iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rose 1.5%. 
<h3 class="wp-block-heading">Top Performers Among Mega-Caps</h3>
<ul>
<li>American Tower Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) rose 1.80% to $232.30.</li>
<li>Duke Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) gained 1.25%, trading at $125.59.</li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) advanced 1.18% to $313.50.</li>
</ul>
The biggest underperformers included:
<ul>
<li>Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) dropped 7.63% to $58.24.</li>
<li>Capital One Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) fell 6.75% to $152.97.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) declined 6.67%, closing at $140.84.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) slid 6.47% to $20.98.</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy">JPMorgan Raises Recession Risk To 60% As &#8216;Largest US Tax Hike&#8217; In 60 Years Hits Global Economy</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Fed Chair Jerome Powell &#x7C; Economic Outlook &#x7C; Apr 4, 2025" width="500" height="281" src="https://www.youtube.com/embed/wuhf8mg4C6k?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Photo: Shuttertock

Macro Economic Events

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Economics

Federal Reserve

Tech

SPDR Dow Jones Industrial Average ETF Trust

INTC

SBUX

iShares Trust Barclays 20+ Year Treasury Bond Fund

Nasdaq 100 Enters Bear Market, Dow In Correction Territory, Traders Await Fed Chair Powell's Remarks

The U.S. Food and Drug Administration (FDA) on Thursday approved Amgen Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Uplizna (inebilizumab-cdon) as the first and only treatment for adult patients with Immunoglobulin <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">G4-related disease (IgG4-RD)</a>.
IgG4-RD is a&nbsp;chronic immune-mediated fibroinflammatory disorder that often manifests with tumor-like masses and/or painless <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44634869/uplizna-inebilizumab-cdon-is-now-the-first-and-only-fda-approved-treatment-for-igg4-related-diseas" rel="noreferrer noopener">enlargement of multiple organs</a>.&nbsp;
This is the second approved indication for Uplizna, which the FDA previously approved for adult patients with AQP4-IgG+ Neuromyelitis Optica Spectrum Disorder (NMOSD) in&nbsp;June 2020.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44307450/amgens-uplizna-shows-improved-symptoms-in-patients-with-muscle-weakness-disorder-over-one-year" rel="noreferrer noopener">Amgen&#8217;s Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year</a>
The FDA also granted Uplizna Orphan Drug Designation for generalized myasthenia gravis (gMG). Regulatory filing activities are underway for gMG, and submission is anticipated to be completed in H1 2025.
The approval is supported by data from the MITIGATE trial. The trial demonstrated the potential of Uplizna to decrease disease activity by reducing flares in patients while maintaining its efficacy and established safety profile.
Key findings from the MITIGATE trial include:
<ul>
<li>There was an 87% reduction in the risk of IgG4-RD flare compared to placebo during the 52-week placebo-controlled period; 10.3% of participants receiving Uplizna experienced a flare compared to 59.7% of participants receiving placebo.</li>
<li>57.4% of participants receiving Uplizna achieved flare-free, treatment-free, and complete remission at Week 52 compared to 22.4% on placebo.</li>
<li>58.8% of participants receiving Uplizna achieved flare-free, corticosteroid-free, and complete remission at Week 52 compared to 22.4% on placebo.</li>
</ul>
<h2 class="wp-block-heading">Amgen Stock Prediction For 2025</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Amgen, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Amgen, the 200-day moving average sits at $306.84, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is below the current price of $309.85. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: AMGN stock is down 1.05% at $306.59 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/04/44644795/brookfield-strikes-9-billion-deal-for-colonial-pipeline-shell-offloads-minority-stake" target="_blank" rel="noreferrer noopener">Brookfield Strikes $9 Billion Deal For Colonial Pipeline—Shell Offloads Minority Stake</a></li>
</ul>
Photo: Shutterstock/JHVEPhoto

FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/03/final-trades-amgen-sabra-health-care-and-kinsale-capital-group.html">Halftime Report Final Trades</a>,&#8221; Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC said Sabra Health Care REIT, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) has an <a href="https://www.benzinga.com/quote/SBRA/analyst-ratings">almost 7% dividend yield.</a>
Supporting this view, Truist Securities analyst Michael Lewis, on March 18, raised the price target on the stock from $17 to $18. The company posted better-than-expected earnings and sales results on Feb. 19 for the fourth quarter.
Joshua Brown of Ritholtz Wealth Management named Kinsale Capital Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) as his final trade.
Kinsale Capital Group announced Thursday that it will release financial results for the first quarter after the closing bell on April 24. Analysts expect the company to report quarterly earnings at $3.22 per share, down from $3.5 per share in the year-ago period. Kinsale Capital projects quarterly revenue of $425.73 million for the recent quarter, compared to $372.79 million a year earlier.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joseph M. Terranova of Virtus Investment Partners picked Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>).
Adding support to his choice, Amgen, on Thursday, announced that the U.S. Food and Drug Administration approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD).
Price Action:
<ul>
<li>Sabra Health Care gained 1.7% to close at $17.65 on Thursday.</li>
<li>Kinsale Capital shares rose 1.4% to close at $498.60 during Thursday's session.</li>
<li>Amgen shares gained 1.4% to settle at $309.85 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44626468/top-3-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 3 Risk Off Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo: Shutterstock

KNSL

SBRA

Amgen, Sabra Health Care And A Financial Stock On CNBC's 'Final Trades'

FDA Approves Amgen's UPLINZA As First And Only Treatment For Immunoglobulin G4-Related Disease

CNBC Halftime Report Final Trades: Amgen, Kinsale Capital Group, Sabra Health Care REIT

Small Cap

Opinion

Press Releases

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Dividends

AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS

UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO

CELC

GNTA

KYKOY

ONCY

TSX:ONC

TYO:4151

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

Amgen

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌